

Renew your 2013 CAEP Membership.

There *is* Strength in Numbers!

Members will receive their 2013 membership
invoices in early November.
Membership must be renewed by December 31, 2012.



For more information visit
caep.ca/membership



Follow us:



For rapid¹ correction of warfarin reversal:

Beriplex[®] P/N

Human Prothrombin Complex



Beriplex[®] P/N Packaging: Beriplex[®] P/N (500 IU), Diluent Vial (20 mL) and Mix2Vial[™].
¹Mix2Vial is a trademark of West or one of its Subsidiaries.

Now available from Canadian Blood Services

- Infusion rate of 8 mL/min²
- Available in a 500 IU vial with a 20 mL diluent vial²
- Room temperature storage up to 36 months²

Indications

Beriplex[®] P/N (Human Prothrombin Complex) is indicated in adults (≥ 18 years of age) for the treatment of bleeding and perioperative prophylaxis of bleeding in acquired deficiency of the prothrombin complex coagulation factors, such as deficiency caused by treatment with vitamin K antagonists, or in case of overdose of vitamin K antagonists, when rapid correction of the deficiency is required².

No adequate study in subjects with congenital deficiency is available. Beriplex[®] P/N can be used for the treatment of bleeding and perioperative prophylaxis of bleeding in congenital deficiency of any of the vitamin K dependent coagulation factors only if purified specific coagulation factor product is not available².

Contraindication:

Beriplex[®] P/N is contraindicated in the following cases: Known hypersensitivity to any of the components of the product; risk of thrombosis, angina pectoris, and recent myocardial infarction (exception: life-threatening haemorrhages following overdose of oral anticoagulants, and before induction of a fibrinolytic therapy); in the case of disseminated intravascular coagulation, prothrombin complex-preparations may only be applied after termination of the consumptive state; known history of heparin-induced thrombocytopenia².

For more information about Beriplex[®] P/N, please refer to the current Product Monograph, available on our website at www.cslbehring.ca.

Beriplex[®] P/N is a Registered Trademark of CSL Behring.

1. A demonstrated rapid decrease in INR (≤1.3) within 30 min after administration of Beriplex[®] P/N².
2. Beriplex[®] P/N (Human Prothrombin Complex), Product Monograph, Nov 5, 2010.



CSL Behring
Biotherapies for Life[™]

CSL Behring Canada Inc.
55 Metcalfe St., Suite 1460
Ottawa, Ontario K1P 6L5
Telephone: 866-773-7721
www.CSLBehring.ca

70% SOLD OUT!


CME in the SUN
...are your bags packed?

REGISTER NOW at CAEP.ca!

CAEP Canadian Association of Emergency Physicians



Club Med, Punta Cana, Dominican Republic - January 26 - February 2, 2013



HAVE YOUR PHOTO ON THE COVER OF CJEM!

ENTER THE 2013 CJEM COVER PHOTO CONTEST

Submit your photos today and be eligible to have your photo on the cover of an upcoming issue of CJEM!

Contest winner also receives complimentary registration to the 2013 CAEP Annual Conference in Vancouver

Visit caep.ca to download contest application forms and to review rules and regulations



DEADLINE FOR ENTRY:
January 31, 2013
5:00 PM EST

Photo contest brought to you by: **CJEM** **JCMU**



BEGINNING IN 2013!

The CAEP CME Resident Initiative

CAEP is taking great strides to ensure that our Resident physicians gain as much knowledge as possible through the CAEP CME Resident Initiative.

Residents who are CAEP members can attend selected Roadshows for as little as \$150

Visit CAEP.ca for details!

CAEP | ACMU
ROADSHOWS

CME That Travels



Knowledge is Power!

